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11C-choline and 18F-FAMT are known to correlate with tumor cell proliferation and amino acid metabolism. We investigated the
ability of 11C-Choline and 18F-FAMT PET in diagnosis of musculoskeletaltumors in thirty-six patients in comparisonof 18F-FDG
PET. 11C-Choline and 18F-FDG PET were positive in all the malignant tumors (n = 13), whereas 18F-FAMT was positive in 11
tumors. The mean SUVs for malignanttumors were signiﬁcantly higher than those for benign lesions in all three tracers imaging.
A moderate correlation was found between 11C-Choline and 18F-FDG (r = 0.540, P<. 05), or 18F-FAMT and FDG (r = 0.596,
P<. 05). The diagnostic sensitivity and speciﬁcity for malignancy were 91.7% and 71.4%, respectively, using 11C-choline with
aS U Vc u t - o ﬀ of 2.69. The sensitivity and speciﬁcity of 18F-FAMT for malignancy were 66.7% and 85.7%, respectively, using a
SUV cut-oﬀ of 1.26. For 18F-FDG, using a SUV cut-oﬀ of 2.77, the sensitivity and speciﬁcity were 83.3% and 71.4%, respectively.
According to ROC analysis, the ROC curves for 11C-Choline, 18F-FAMT, and 18F-FDG were 0.855, 0.734, and 0.847, respectively.
11C-Choline PET is superior in the visualization of musculoskeletal tumors with high contrast imaging, whereas the combination
of 18F-FAMT and 18F-FDG PET provides valuable information for the preoperative planning in patients with musculoskeletal
tumors.
1.Introduction
Musculoskeletal tumors generally present clinically as large
masses that are often heterogeneous and have diﬀerent
biological behaviors. The diagnosis and treatment of such
lesions is often complex [1]. Generally, the anatomical
imaging methods, such as conventional radiology, CT, and
MRI, are very important for the assessment of tumor
location, form, size, inﬁltration, and extent. However, the
radiographic appearance of many tumors is indeterminate,
especially CT and MRI have limited ability to allow distinc-
tion of malignant from benign lesions and ﬁnal diagnosis
may only be achieved using biopsy and histopathologic
evaluation. Furthermore, in case of large-size tumors, the
highest-grade part ofthe lesion may be missed on a biopsy of
only a small region [2]. This results in errors in the diagnosis
and grading of the tumor and thus suboptimal management
of the disease. An imaging technique that enables reliable
distinctionofmalignantfrombenignmusculoskeletallesions
would thus be of considerable clinical value.
During the last decade, positron emission tomography
(PET) has become an essential tool in the management of
a growing number of cancer patients [3–5]. 2-[18F]ﬂuoro-
2-deoxy-D-glucose (18F-FDG) is by far the most common
radiopharmaceutical for PET in clinical use and has shown
a high sensitivity for diagnosing and staging a wide variety of
malignant diseases. However, there are several limitations for
theuseof 18F-FDGindiscriminatingbenignlesionsfromsoft2 Journal of Biomedicine and Biotechnology
tissue sarcomas [6]. Glucose metabolism is not signiﬁcantly
increasedinsomebonetumortypes[7].Themostsigniﬁcant
drawback of 18F-FDG for oncologic purpose results from
the absence of speciﬁcity for musculoskeletal tumor [8].
Infection, inﬂammation, granulomatous diseases, and many
other physiologic or pathologic conditions can also show
high 18F-FDG uptake. To overcome these limitations, new
PET imaging agents and its applications are required.
So far, only few PET imaging agentshave been developed
and used for the detection of musculoskeletal tumors.
One potential imaging agent is radiolabeled amino acid,
which can be used as the marker of cell proliferation and
microvessel density of the tumors [3, 9]. Various studies
have demonstrated that increased uptake of amino acid
compound is predominantly due to a higher L-amino acid
transporter (LAT) activity. Transport of the amino acid into
thecellcanbefollowedbyrapidmetabolizationandtrapping
inside the cell, for example, as in the case for L-3-[18F]-6
α-methyltyrosine (18F-FAMT). Although the exact trapping
mechanism isnotknown,thisselectiveuptakepatternresults
in a very high tumor-to-background (T/B) ratio enabling
clear delineation of the tumor [10–12].
Another attractive imaging agent is [methyl-11C] choline
(11C-choline), which has been increasingly used for the
evaluation of various cancers [4]. Choline is quaternary
amine that is ubiquitously distributed in cells, mostly in
the form of phospholipids. In vivo and in vitro studies
have shown that the increased 11C-choline uptake in the
tumor cells is proportional to the rate of tumor duplication
[13–15]. 11C-choline PET imaging shows that liver and
kidney are the major sites for choline oxidation or excretion;
negligible activity is present in the bone and soft tissues,
which indicates its noteworthy advantage for the detection
of musculoskeletal tumors.
Since the diﬀerences in uptake mechanism are present, it
will be interesting to ﬁnd out the correlations and diﬀerences
in the patterns of PET imaging of 18F-FDG, 18F-FAMT and
11C-choline, especially during the same time period within
the same setting. However, until now, there has as yet only
limited experience of use of 18F-FAMT and 11C-choline PET
in patients with musculoskeletal tumors [4, 16]. The aim
of this study was to compare the characteristics of 18F-
FDG, 18F-FAMT, and 11C-choline PET for the detection of
musculoskeletal tumors in the same patient population.
2.Materialsand Methods
2.1. Patients. Thirty-six consecutive patients (14 female and
22 male; age range: 11 to 84 years) with or suspected of hav-
ingmalignanciesinthemusculoskeletalsystem wereenrolled
inthisprospectivestudy.Allthepatientsunderwent 18F-FDG
PET, 18F-FAMT, 11C-choline, and computed tomography
(CT) or magnetic resonance imaging (MRI) in a random
order within a maximum interval of 2 weeks. No therapeutic
medication has been changed during this period, and none
of the patients had diabetes mellitus. The blood glucose level
during the PET study was ranged from 64 to 95mg/dL (3.5–
5.3mmol/L). Patients had surgical operation or biopsy after
the completion of the above imaging examinations based on
the information of tumor PET imaging and CT and MRI
images, and the resected tumor specimens were submitted
for the pathological diagnosis. The imaging protocols of 18F-
FDG PET, 18F-FAMT, and 11C-choline were approved by
the Institutional Review Board of the Institute of Gunma
University. Informed consents of this study were obtained
from all patients.
2.2. PET Imaging. PET imaging agents of 18F-FDG, 18F-
FAMT, and 11C-choline were prepared using a cyclotron
and automated synthetic apparatuses that were reported by
Hamacher et al. [17], Tomiyoshi et al. [10], and Hara and
Yuasa [13], respectively. PET scans were performed with a
SET-2400W(Shimadzu Corporation, Kyoto,JAPAN), which
had a large 20cm axial ﬁeld of view and 59.5cm transaxial
ﬁeld of view, giving 63 two-dimensional imaging planes.
The transaxial spatial resolution was 4.2mm full width at
half maximum (FWHM) at the center of the ﬁeld of view,
and the axial resolution was 5.0mm FWHM. Each patient
had an overnight fasting before 18F-FDG, 18F-FAMT, and
11C-choline PET. 18F-FDG and 18F-FAMT PET were started
40min after the administration of approximately 320MBq
18F-FDG and 260MBq 18F-FAMT, and static image data
was acquired for 8min per bed position, respectively. 11C-
choline PET was performed 5min after the intravenous
injection of approximately 370MBq 11C-choline, and static
image data was acquired for 5min per bed position. PET
data was acquired by simultaneous transmission-emission
method [18].Images were reconstructed by the ordersubsets
expectation maximization (OSEM) algorithm into a 128 ×
128 matrix with pixel dimensions of 4.0mm in plane and
3.125mm axially. The image with 9.4mm thickness was
generated for interpretation and semiquantitative analysis.
2.3. Image Analysis. PET images were separately interpreted
by two nuclear medicine physicians until consensus was
reached. Clinical information and conventional images such
as radiographys, CT scans, and MRI images were available at
the time of image interpretation. The 18F-FDG, 18F-FAMT,
and 11C-choline uptakes were evaluated by both qualitative
and semiquantitative methods. The qualitative analysis was
performed by the visual evaluation of tumor tracer uptake.
Tumor lesions were identiﬁed as areas of focally increased
uptake, exceeding that of surrounding tissues or organs. The
degree of tracer uptake was visually classiﬁed as negative (−)
and positive (+ or ++) results. The semiquantitative analysis
was performed using the standardized uptake value (SUV).
The regions of interest (ROI) in 1cm diameter were drawn
on the lesions including the highest activity. SUV was then
determined as the average of the radioactivity in the tumors
divided by the injected radioactivity normalized to the body
weight. The mean value per pixel in the ROI for assessing
SUV was employed for semiquantitative analysis. All PET
ﬁndings were ﬁnally compared with CT and/or MRI images,
and the results of pathological diagnosis.
2.4. Statistical Analysis. Data were expressed as mean ± SD
or total number (%). A linear regression analysis wasJournal of Biomedicine and Biotechnology 3
Table 1: Patient characteristics and results of PET studies.
Patient no. Age Sex Histological
diagnosis Grade Location Lesion
size (mm)
Choline FAMT FDG
Visual SUV Visual SUV Visual SUV
Benign
1 44 F Xanthoﬁbroma — Tibia 40 × 40 × 40 ++ 4.90 ++ 1.10 ++ 3.30
2 51 F Enchondroma — Scapular 27 × 30 × 60 + 0.75 + 0.72 + 0.70
35 0 M
No deﬁnite
residual tumor
cells
—K n e e 5 0 × 50 × 50 ++ 0.98 ++ 1.24 ++ 1.74
4 58 M Schwannoma — Thigh 35 × 35 × 35 ++ 1.80 + 0.71 ++ 1.70
55 9 F Bursitis with
synovitis —K n e e 2 0 × 20 × 20 ++ 1.13 — — + 0.60
61 5 F Eosinophilic
granuloma — Eosinophilic 30 × 30 × 55 ++ 2.20 ++ 0.90 ++ 2.69
7 57 M Fibroma — Scapula 30 × 30 × 50 + 0.62 ++ 1.70 ++ 1.53
8 62 F Schwannoma — Carpal 5 × 9 × 10 ++ 1.50 ++ 0.91 ++ 1.80
9 60 M Neuroﬁbroma — Femur 50 × 60 × 150 ++ 5.10 ++ 1.40 ++ 3.49
10 53 M Giant cell tumor — Knee 35 × 35 × 35 ++ 4.20 + 0.65 ++ 4.36
11 53 M Degeneration of
skeletal muscle —L o w e r l e g 2 7 × 30 × 60 ++ 0.90 + 0.74 + 0.60
12 26 F Giant cell tumor — Femur 28 × 31 × 42 ++ 8.00 ++ 1.10 ++ 8.39
13 15 F Desmoid tumor — Lower leg 40 × 60 × 70 ++ 3.30 + 0.76 ++ 2.20
14 27 F Giant cell tumor — Knee 30 × 30 × 40 ++ 1.12 + 0.71 ++ 3.23
15 48 M Desmoid tumor — Carpal 30 × 40 × 60 ++ 3.10 ++ 1.00 ++ 2.77
16 61 M Desmoid tumor — Back 40 × 40 × 70 ++ 2.30 ++ 1.17 ++ 2.14
17 55 M Lymphangioma — Knee 30 × 40 × 50 ++ 1.69 ++ 0.92 ++ 1.37
18 51 M Lymphangioma — Axilla 30 × 40 × 50 ++ 1.70 ++ 1.26 ++ 2.10
19 31 M Schwannoma — Lower leg 10 × 20 × 30 ++ 0.88 + 0.56 ++ 0.81
20 47 M Desmoid tumor — Thigh 65 × 46 × 68 ++ 2.46 ++ 1.64 ++ 3.27
21 58 M Aseptic necrosis — Talus 30 × 30 × 30 ++ 2.40 ++ 1.20 ++ 1.74
22 20 M
Pigmented
villonodular
synovitis
—P o p l e s 3 0 × 30 × 50 ++ 2.69 ++ 0.86 ++ 2.60
23 53 F Degenerative joint
disease —F e m u r 4 0 × 70 × 110 ++ 2.24 + 0.58 ++ 2.40
Malignant
24 47 M Liposarcoma 1 Thigh 70 × 70 × 120 ++ 0.82 — — + 0.61
25 43 F Osteosarcoma 2 Tibia 20 × 24 × 55 ++ 9.30 ++ 2.00 ++ 6.00
26 53 F Malignant
lymphoma 3C l a v i c l e 2 7 × 28 × 30 ++ 4.50 ++ 0.91 ++ 4.90
27 17 M Ewing’s sarcoma 3 Femur 54 × 50 × 150 ++ 2.60 + 0.58 ++ 0.89
28 54 F Metastatic
carcinoma 3C a r p a l 5 0 × 50 × 60 ++ 9.00 ++ 1.06 ++ 3.19
29 83 F Malignant
lymphoma 3F e m u r 5 0 × 80 × 196 ++ 7.30 ++ 7.00 ++ 14.49
30 12 M Osteosarcoma 3 Femur 50 × 50 × 60 ++ 6.40 ++ 2.62 ++ 3.15
31 14 F Osteosarcoma 3 Femur 60 × 70 × 160 ++ 4.12 ++ 1.27 ++ 13.66
32 11 M Osteosarcoma 3 Femur 60 × 70 × 170 ++ 3.68 ++ 2.12 ++ 4.90
33 12 M Osteosarcoma 3 Femur 50 × 100 × 140 ++ 3.03 ++ 1.38 ++ 5.374 Journal of Biomedicine and Biotechnology
Table 1: Continued.
Patient no. Age Sex Histological
diagnosis Grade Location Lesion
size (mm)
Choline FAMT FDG
Visual SUV Visual SUV Visual SUV
34 64 M Myeloma 3 Sacrum 40 × 51 × 60 ++ 3.60 ++ 1.80 ++ 2.55
35 84 M Liposarcoma 3 Femur 230 × 280 × 360 ++ 3.20 — 0.30 ++ 6.00
36 44 M Metastatic
carcinoma 3F e m u r 1 1 × 22 × 40 ++ 5.10 ++ 1.90 ++ 1.90
(a) (b) (c) (d)
Figure 1: A 43-year-old female with osteosarcoma. 18F-FDG (SUV = 6.0) (a), 18F-FAMT (SUV = 2.0) (b), and 11C-choline (SUV = 9.3) (c)
demonstrated high tracer uptake in the tumor of the left tibia, which corresponded to the area that was enhanced on MRI image (d).
Table 2: Results of the ROC analysis of FDG, FAMT, and choline
PET in musculoskeletal tumors.
Tracer AUC SUV
cutoﬀ
Sensitivity
(%)
Speciﬁcity
(%)
Accuracy
(%)
FDG 0.847 2.77 83.3 71.4 69.7
FAMT 0.734 1.26 66.7 85.7 78.8
Choline 0.855 2.69 91.7 71.4 78.8
AUC: area under the ROC curve.
performed for the correlation study. A multiple comparison
test and t-test were used for the statistical analysis. A receiver
operating characteristic (ROC) analysis was performed to
compare the diagnostic abilities of 18F-FDG, 18F-FAMT, and
11C-choline PET. A P value <.05 was considered statistically
signiﬁcant.
3.Results
This study population included 36 patients with 36 muscu-
loskeletal lesions. Patient clinical characteristics and imaging
ﬁndings of 11C-choline, 18F-FAMT, and 18F-FDG PET were
summarized in Table 1. Three typical cases are illustrated in
Figures 1, 2,a n d3.
3.1. Visual Analysis. In all 36 patients, 13 patients had
malignant tumors and 23 had benign lesions, based on
pathological ﬁndings of biopsy or surgical specimens. The
diameter of the lesions ranged from 5 × 9 × 10mm to
230 × 280 × 360mm as determined by CT, MRI, or
dissected surgical specimen. 11C-choline and 18F-FDG PET
waspositiveinall the36patients(100%),whereas 18F-FAMT
PETimaging were positive in 33 patients(84%) and negative
in 3 patients (1 bursitis with synovitis and 2 liposarcoma).
3.2. Semiquantitative Analysis. The mean (±SD) SUVs for
malignant tumors were signiﬁcantly higher than those for
benign lesions in all 18F-FDG, 18F-FAMT, and 11C-choline
PET analysis (5.2 ± 4.3, n = 13versus 2.5 ± 1.7, n = 23,
P<. 002; 1.9 ± 1.7, n = 13 versus 1.0 ± 0.3, n = 23, P<. 02;
4.8 ± 2.5, n = 13 versus 2.4 ± 1.8, n = 23, P<. 001, resp.).
The P valueshowed a trend ofsigniﬁcant relationship as 11C-
choline >18F-FDG >18F-FAMT for distinguishing malignant
tumors from benign lesions.
As shown in Figure 4, the mean SUV of 18F-FDG and
11C-choline was signiﬁcantly higher than that of 18F-FAMT
in either malignant tumors or benign tumors (P<. 002,
P<. 001 and P<. 0001, P<. 0002, resp.), but there was
no signiﬁcant diﬀerence between 18F-FDG and 11C-choline
in either malignant tumors or benign tumors (n.s.).
The linear regression analysis was performed between
11C-choline and 18F-FDG, as well as 18F-FAMT and 18F-FDG
(Figure 5). Moderate correlations were noted between 11C-
choline and 18F-FDG in all lesions (r = 0.540, n = 36) and
18F-FAMT and 18F-FDG (r = 0.596, n = 36).
3.3. ROC Analysis. The results of ROC analysis using
histopathological diagnosis as the gold standard were shown
inFigure 6.Theareaunderthecurve(AUC)of 18F-FDGPET,
18F-FAMT, and 11C-choline PET was 0.847,0.734, and 0.855,
respectively. Table 2 summarized the sensitivity, speciﬁcity,
and accuracy of 18F-FDG, 18F-FAMT, and 11C-choline PET.
For example, in 18F-FDG PET, the sensitivity, speciﬁcity, and
accuracy were 83.3%, 71.4%, and 69.7%, respectively, when
2.77 of SUV was used as a cutoﬀ. This would be 66.7%,
85.7%, and 78.8%, respectively, for 18F-FAMT as using a
cutoﬀ of SUV 1.26. 11C-choline PET was 91.9%, 71.4%,
and 78.8%, respectively, when 2.69 of SUV was used as a
cutoﬀ. The trend observed in the ROC analysis was that 18F-
FDG PET and 11C-choline PET had almost the same detectJournal of Biomedicine and Biotechnology 5
(a) (b) (c) (d)
Figure2:A53-year-oldmalewithgiantcelltumorintheleftknee. 18F-FDG (SUV=4.36)(a)and 11C-choline(SUV=4.20)(c)demonstrated
high tracer uptake in the tumor of the left knee, whereas 18F-FAMT (SUV = 0.65) (b) showed mild uptake, which corresponded to the area
that was shown on MRI image (d).
(a) (b) (c) (d)
Figure 3: A 60-year-old male with neuroﬁbroma in the left femur. 18F-FDG (SUV = 3.49) (a), 18F-FAMT (SUV = 1.40) (b), and 11C-choline
(SUV = 5.10) (c)showed cleartracer uptake in the tumorof the left femur, which corresponded to the area that wasenhanced on MRI image
(d).
FDG FAMT Choline FDG FAMT Choline
Malignant lesions Benign lesions
1.9 ±1.7
4.8 ±2.5
2.4 ±1.6 2.4 ±1.8
5.2 ±4.3
P<. 002
P<. 001
P<. 0001 P<. 0002
n.s.
n.s.
P<. 002
P<. 02
P<. 001
1 ±0.3
0
5
10
15
20
25
(
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V
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Figure4:Standardizeduptakevalue(SUV)of 18F-FDG, 18F-FAMT,
and 11C-choline in malignant and benign lesions. 18F-FDG, 18F-
FAMT, and 11C-choline revealed signiﬁcant higher SUV in malig-
nant lesions than in benign lesions (P<. 002, P<. 02, and P<
.001, resp.). Diﬀerences of tumor SUVs between 18F-FDG and 11C-
choline were not signiﬁcant in both malignant and benign lesions,
whereas both 18F-FDG and 11C-choline SUVs were signiﬁcantly
higher than that of 18F-FAMT.
abilityinthispatientpopulationandshowedbetterdetection
performance than that of 18F-FAMT PET.
4.Discussion
The results of the present study indicate that 11C-choline
and 18F-FDG PET perform better than 18F-FAMT in the
detection of musculoskeletal tumors on the whole data
analysis. However, in some benign lesions, such as bursitis
or synovitis, 18F-FAMT PET performed better than 11C-
choline and 18F-FDG PET in visualizing focal lesions. On the
other hand, 11C-choline and 18F-FAMT PET showed higher
contrast compared with 18F-FDG PET. Our ﬁndings were
interpreted based on the pathological ﬁndings and analyzed
to compare simultaneously the 3 PET imaging modalities.
Unsurprisingly, 18F-FDG PET detected all the malignant
tumors successfully; however, some benign lesions, such as
benign giant cell tumor, desmoids tumor, and synovitis, also
showed focal intensive uptakes. Although 18F-FDG PET has
been widelyused fortheevaluationofvarioustumors, recent
reports suggested that 18F-FDG PET could not be used as a
screening method for diﬀerential diagnosis between benign
and malignant musculoskeletal lesions. A high accumulation
of 18F-FDG can be observed in histiocytic, ﬁbroblastic, and
some neurogenic lesions, regardless of whether they are
benign or malignant. More speciﬁc uses of 18F-FDG PET,
such as grading, staging, and monitoring of musculoskeletal
sarcomas, should be considered for each tumor of a diﬀerent
histologic subtype [19].
The original application of 11C-choline was for detection
of braintumorand prostatecancer[20, 21]. 11C-choline PET
can give clearer images of brain tumors, whereas 18F-FDG
PET does not always delineate the border of the tumor. The
high uptakeof 18F-FDGinthenormal braintissuefrequently
obscures the tumor uptake. Our present results showed
that all the malignant tumors showed signiﬁcant intensive
accumulationin 11C-cholinePETimaging.This wassuperior6 Journal of Biomedicine and Biotechnology
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Figure 5:Relationship among 18F-FDG, 18F-FAMT, and 11C-choline uptakes inmusculoskeletaltumors.Moderate correlation wasobserved
between 11C-choline uptake and 18F-FDG uptake, and 18F-FAMT and 18F-FDG in all lesions.
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Figure6:Comparisonamong 18F-FDG, 18F-FAMT, and 11C-choline
PETindiﬀerential diagnosisbetween malignanttumorsandbenign
lesions by ROC analysis in musculoskeletaltumors.
to 18F-FDG PET and 18F-FAMT in diﬀerentiation between
malignant and benign lesions. Thus, 11C-choline PET might
be useful as a screening method for malignant bone and
soft tissue tumors. The application of 11C-choline PET in
evaluation of bone and soft tissue tumors is not yet well
known.
Similarly, 18F-FAMTwas also developedforthedetection
of brain tumors [22]. Watanabe et al. previously reported
that 18F-FAMT may be superior to 18F-FDG in the diﬀerenti-
ation between benign and malignant tumors, while 18F-FDG
may be the betterchoice for noninvasive malignancy grading
[16].Inthepresentpatientpopulation,the 18F-FAMTuptake
was signiﬁcantly higher in malignant tumors than in benign
lesions, which partly supported the previous study.
To the best of our knowledge, this is the ﬁrst study to
compare the clinical utility of 18F-FDG, 18F-FAMT, and 11C-
choline PET in detection of musculoskeletal tumors in a
same patient population. We found that 11C-choline PET
could detect and diﬀerentiate malignant musculoskeletal
tumors with high sensitivity, as well as 18F-FDG PET,
compared with 18F-FAMT PET. Based on visual evaluation,
PET imaging clearly demonstrated intensive radioactive
accumulation in 100% of the musculoskeletal tumors by
using18F-FDG and 11C-choline, but only 84% if using 18F-
FAMT. The uptakes of all the 3 imaging agents, 18F-FDG,
18F-FAMT, and 11C-choline, were signiﬁcantly higher in
malignant musculoskeletal tumors than those in benign
lesions. 11C-choline and 18F-FDG showed equal ability in
detection of musculoskeletal tumors, followed by 18F-FAMT.
A considerable overlap of SUVs was observed in the
present study, due to a relatively large number of benign
cases with various histological typesincluded.Itisnoted that
high 11C-choline uptake (SUV > 2.4) was found in 2 of 3
giant cell tumors, 3 of4 desmoid tumors, 1 xanthoﬁbroma, 1
neuroﬁbroma, and 1 pigmented villonodular synovitis. Such
false-positive cases were similar in 18F-FDG PET. High FDG
uptake (SUV > 2.4) was noted in all 3 giant cell tumors,
2 of 4 desmoid tumors, 1 xanthoﬁbroma, 1 neuroﬁbroma,Journal of Biomedicine and Biotechnology 7
1 eosinophilic granuloma, and 1 pigmented villonodular
synovitis. Most of the false-positive cases in this study
could be classiﬁed as histiocytic or giant cell-containing
lesions [23, 24]. Histiocytes and giant cells in a tissue
are in monocyte-macrophage lineage. Macrophages play a
central role in the host response to injury and infection,
and their energy is predominantly supplied by means of
intracellular glucose metabolism [25, 26]. High uptake of
18F-FDG in inﬂammatory lesions found in this study was
consistent with previous studies [27–29]. Although it is still
controversial whether histiocytes and giant cells in primary
bone tumors are reactive or neoplastic, these cells might
partially contribute to the high uptake of 18F-FDG in the
benignboneand soft tissuelesions [30].Itmay bereasonable
to consider that high uptake of 11C-choline in reactive or
neoplasticcellsofhistiocytesandgiantcellsisduetothehigh
11C-choline utilization by these cell membranes. Further
investigation is necessary to verify this point. The overlap
of SUVs was also observed in 18F-FAMT PET. High 18F-
FAMT uptake (SUV > 1.0) was found in 1 of 3 giant cell
tumors, 2 of 4 desmoid tumors, 1 xanthoﬁbroma, 1 ﬁbroma,
1 neuroﬁbroma, 1 lymphangioma, and 1 aseptic necrosis.
This may also be explained from the above reasons.
The diﬀerentiation of malignant from benign lesions is
crucial to preoperative planning for treatment of muscu-
loskeletal tumors. This study in the current patient popu-
lation showed that the sensitivity of 11C-choline PET was
higher than that of 18F-FDG PET in musculoskeletal tumors.
This is consistent with our previous study [31], which
could be explained as follows. A high uptake of 18F-FDG
in tumors is accomplished only if the tumor metabolism is
biased towardexcessive glycolysisby activation of theglucose
transporter and hexokinase [32]. This may occur, although
there seemed to be rare exceptions, if the tumor size is large
andthetumorenvironmentishypoxicbecauseofinsuﬃcient
blood(oxygen)supply.Incontrast, theuptakeof 11C-choline
in tumors is the result of cell membrane synthesis. When
11C-choline is incorporated in tumors, it is rapidly phos-
phorylated(yielding 11C-phosphorylcholine) andchemically
trapped inside the cell membranes. 11C-phosphorylcholine
may be the major chemical derived from 11C-choline at
the time of PET scanning. Thereafter, it is further metab-
olized and converted to 11C-phosphatidylcholine and then
integrated in tumor cell membrane [33]. This is the only
metabolic pathway known for choline in tumors, although
there are other metabolic pathway in other normal organs.
Thus, it could be assumed that the 11C-choline uptake in
tumors is proportional to the tumor cell proliferation rate
[15]. When the cut-oﬀ value was set at 1.26, the sensitivity
of 18F-FAMT PET for correctly diagnosing malignancy was
66.7% with a speciﬁcity of 85.7%, resulting in an accuracy of
78.8%. The sensitivity of 18F-FAMT PET was lower than that
of 18F-FDG and 11C-choline, whereas it is noteworthy that
the speciﬁcity was clearly higher than that of 18F-FDG and
11C-choline.
In this study, we did not evaluate the ability of the agents
in grading of malignancy, due to the small histopathological
types and tumor grades. Almost all the tumors were in
Grade 3. It should be noted that almost all (12/13) the
malignant musculoskeletal tumors were correctly diagnosed
by 11C-choline PET using a cutoﬀ of 2.6 of SUV. It is
recommended that 11C-choline PET might be used as a
screening method for malignant musculoskeletal tumors.
Watanabeetal.reported[16],ina75musculoskeletaltumors
patients study, that 18F-FAMT appeared to be inferior to 18F-
FDG with regard tomalignancy grading, and the lattertracer
consequently may be more useful for noninvasive grading
in the surgical staging of musculoskeletal sarcoma. Use of
18F-FAMT PET in combination with 18F-FDG PET might
be a useful approach for preoperative planning in patients
with musculoskeletal tumors. Due to the diﬀerences in the
accumulation mechanisms of the 3 imaging agents and the
diﬀerence in patient selection, larger patient populations
might be consideredtodetermine which agent is more useful
for evaluating the histological grade of musculoskeletal
tumors.
5.Conclusion
Our ﬁndings indicate that 11C-choline, 18F-FDG, and 18F-
FAMTare useful agentsfor the evaluationofmusculoskeletal
tumors.Inparticular, 11C-cholinemaybesuperiortothe 18F-
FDG and 18F-FAMT in detection of musculoskeletal tumors
and, thus, may be important for preoperative planning. The
use of 18F-FAMT PET in combination with 18F-FDG or 11C-
choline PET might be a useful approach for preoperative
planning in patients with musculoskeletal tumors. The
high uptake of 18F-FDG and 11C-choline in some benign
musculoskeletal tumors and tumor-like lesions, especially
histiocytic and giant cell-containing lesions, should be aware
of in clinical practice.
Acknowledgments
This study was partially supported by grants from the Min-
istry of Education, Culture, sports, science and Technology
of the Japanese Government. Dr. H. Zhang was supported
by a key project Grant (2006DFB32940) and by the National
Basic Research Program (2011CB504400) from the Ministry
of Science and Technology of China.
References
[1] H. Jadvar, S. Gamie, L. Ramanna, and P. S. Conti, “Muscu-
loskeletal system,” Seminars in Nuclear Medicine,v o l .3 4 ,n o .
4, pp. 254–261, 2004.
[2] K. L. Verstraete, H. J. VanderWoude, P. C. Hogendoorn, Y.
DeDeene, M. Kunnen, and J. L. Bloem, “Dynamic contrast-
enhanced MR imaging of musculoskeletal tumors: basic prin-
ciples andclinicalapplications,”Journal of MagneticResonance
Imaging, vol. 5, pp. 311–321, 1996.
[3] H. Zhang, K. Yoshikawa, K. Tamura et al., “11C-methionine
positron emission tomography and survival in patients with
bone andsofttissuesarcomastreated bycarbonionradiother-
apy,” Clinical Cancer Research, vol. 10, no. 5, pp. 1764–1772,
2004.
[4] M. Tian, H. Zhang, N. Oriuchi, T. Higuchi, and K. Endo,
“Comparison of 11C-choline PET and FDG PET for the
diﬀerential diagnosis of malignant tumors,” European Journal8 Journal of Biomedicine and Biotechnology
of Nuclear Medicine and Molecular Imaging,v o l .3 1 ,n o .8 ,p p .
1064–1072, 2004.
[5] M. Tian, H. Zhang, Y. Nakasone, K. Mogi, and K. Endo,
“Expression of Glut-1 and Glut-3 in untreated oral squamous
cell carcinoma compared with FDG accumulation in a PET
study,” European Journal of Nuclear Medicine and Molecular
Imaging, vol. 31, no. 1, pp. 5–12, 2004.
[6] O. E. Nieweg, J. Pruim, R. J. van Ginkel et al., “Fluorine-
18-ﬂuorodeoxyglucose PET imaging of soft-tissue sarcoma,”
Journal of Nuclear Medicine, vol. 37, no. 2, pp. 257–261, 1996.
[7] A. C. Kole, O. E. Nieweg, H. J. Hoekstra, J. R. Van Horn, H.
S. Koops, and W. Vaalburg, “Fluorine-18-ﬂuorodeoxyglucose
assessment of glucose metabolism in bone tumors,” Journal of
Nuclear Medicine, vol. 39, no. 5, pp. 810–815, 1998.
[8] H. Watanabe, T. Shinozaki, T. Yanagawa et al., “Glucose
metabolic analysisofmusculoskeletaltumours using ﬂuorine-
18-FDG PET as an aid to preoperative planning,” Journal of
Bone and Joint Surgery, vol. 82, no. 5, pp. 760–767, 2000.
[ 9 ]P .L .J a g e r ,W .V a a l b u r g ,J .P r u i m ,E .G .E .D eV r i e s ,K .J .
Langen, and D. A. Piers, “Radiolabeled amino acids: basic
aspects and clinical applications in oncology,” Journal of
Nuclear Medicine, vol. 42, no. 3, pp. 432–445, 2001.
[10] K. Tomiyoshi, K. Amed, S. Muhammad et al., “Synthesis
of isomers of 18F-labelled amino acid radiopharmaceutical:
position 2- and 3-L-18F-α-methyltyrosine using a separation
and puriﬁcation system,” Nuclear Medicine Communications,
vol. 18, no. 2, pp. 169–175, 1997.
[11] T. Inoue, K. Tomiyoshi, T. Higuichi et al., “Biodistribu-
tion studies on L-3-[Fluorine-18]Fluoro-α-methyl tyrosine: a
potential tumor-detecting agent,” Journal of Nuclear Medicine,
vol. 39, no. 4, pp. 663–667, 1998.
[12] R. Kumar, H. Dhanpathi, S. Basu, D. Rubello, S. Fanti, and
A. Alavi, “Oncologic PET tracers beyond [(18)F]FDG and
the novel quantitative approaches in PET imaging,” Quarterly
Journal ofNuclear Medicineand MolecularImaging,vol.52,no.
1, pp. 50–65, 2008.
[13] T. Hara and M. Yuasa, “Automated synthesis of [11C]choline,
a positron-emittingtracer for tumor imaging,”Applied Radia-
tion and Isotopes,vol. 50, no. 3, pp. 531–533, 1999.
[ 1 4 ]O .K o b o r i ,Y .K i r i h a r a ,N .K o s a k a ,a n dT .H a r a ,“ P o s i t i o n
emission tomography of esophageal carcinoma using (11)C-
choline and (18)F-ﬂuorodeoxyglucose: a novel method of
preoperative lymph node staging,” Cancer, vol. 86, no. 9, pp.
1638–1648, 1999.
[15] T. Hara, K. Inagaki, N. Kosaka, and T. Morita, “Sensitive
detection ofmediastinallymphnodemetastasisoflungcancer
with 11C-cholinePET,”JournalofNuclearMedicine,vol.41,no.
9, pp. 1507–1513, 2000.
[ 1 6 ]H .W a t a n a b e ,T .I n o u e ,T .S h i n o z a k ie ta l . ,“ P E Ti m a g i n go f
musculoskeletel tumours with ﬂuorine-18 α-methyltyrosine:
comparison with ﬂuorine-18 ﬂuorodeoxyglucose PET,” Euro-
pean Journal of Nuclear Medicine, vol. 27, no. 10, pp. 1509–
1517, 2000.
[ 1 7 ]K .H a m a c h e r ,H .H .C o e n e n ,a n dG .S t o c k l i n ,“ E ﬃcient
stereospeciﬁc synthesis of no-carrier-added 2-[18F]-ﬂuoro-
2-deoxy-D-glucose using aminopolyether supported nucle-
ophilic substitution,” Journal of Nuclear Medicine, vol. 27, no.
2, pp. 235–238, 1986.
[18] H. Zhang, T. Inoue, S. Alyafei, M. Tian, N. Oriuchi, and
K. Endo, “Tumour detectability in 2-dimensional and 3-
dimensional positron emission tomography using the SET-
2400W:a phantom study,” Nuclear Medicine Communications,
vol. 22, no. 3, pp. 305–314, 2001.
[19] J.Aoki,K. Endo, H. Watanabeet al.,“FDG-PET for evaluating
musculoskeletal tumors: a review,” Journal of Orthopaedic
Science, vol. 8, no. 3, pp. 435–441, 2003.
[20] N. Shinoura, M. Nishijima, T. Hara et al., “Brain tumors:
detection with C-11 choline PET,” Radiology, vol. 202, no. 2,
pp. 497–503, 1997.
[21] T. Hara, N. Kosaka, and H. Kishi, “PET imaging of prostate
cancer using carbon-11-choline,” Journal of Nuclear Medicine,
vol. 39, no. 6, pp. 990–995, 1998.
[22] T. Inoue, T. Shibasaki, N. Oriuchi et al., “F-18 α-methyl
tyrosine PET studies in patients with brain tumors,” Journal
of Nuclear Medicine, vol. 40, no. 3, pp. 399–405, 1999.
[23] J. Johnston, “Giant cell tumor of bone. The role of the giant
cell in orthopedic pathology,” Orthopedic Clinics of North
America, vol. 8, no. 4, pp. 751–770, 1977.
[ 2 4 ]L .L i n g ,M .J .K l e i n ,H .A .S i s s o n s ,G .C .S t e i n e r ,a n dR .
J. Winchester, “Expression of Ia and monocyte-macrophage
lineage antigens in giant cell tumor of bone and related
lesions,” Archives of Pathology and Laboratory Medicine,v o l .
112, no. 1, pp. 65–69, 1988.
[25] K. M´ esz´ aros, G. J. Bagby, and J. J. Spitzer, “Contribution of
diﬀerent organs to increased glucoseconsumptionafter endo-
toxin administration,”The Journal of Biological Chemistry,v o l .
262, no. 23, pp. 10965–10970, 1987.
[ 2 6 ]R .L .G a m e l l i ,H .L i u ,L .K .H e ,a n dC .A .H o f m a n n ,“ A u g -
mentations of glucose uptake and glucose transporter-1 in
macrophages following thermal injury and sepsis in mice,”
Journal of Leukocyte Biology, vol. 59, no. 5, pp. 639–647, 1996.
[27] A. Guhlmann, D. Brecht-Krauss, G. Suger et al., “Chronic
osteomyelitis: detection with FDG PET and correlation with
histopathologic ﬁndings,” Radiology, vol. 206, no. 3, pp. 749–
754, 1998.
[ 2 8 ]W .E .P a l m e r ,D .I .R o s e n t h a l ,O .I .S c h o e n b e r ge ta l . ,“ Q u a n -
tiﬁcation of inﬂammation in the wrist with gadolinium-
enhanced MR imaging and pet with 2-[F-18]-ﬂuoro-2-deoxy-
D-glucose,” Radiology, vol. 196, no. 3, pp. 647–655, 1995.
[ 2 9 ]L .H .B r u d i n ,S .O .V a l i n d ,C .G .R h o d e se ta l . ,“ F l u o r i n e - 1 8
deoxyglucose uptake in sarcoidosis measured with positron
emission tomography,” European Journal of Nuclear Medicine,
vol. 21, no. 4, pp. 297–305, 1994.
[30] J.Aoki,H.Watanabe,T.Shinozakietal.,“FDGPETofprimary
benignandmalignantbonetumors:standardizeduptakevalue
in 52 lesions,” Radiology, vol. 219, no. 3, pp. 774–777, 2001.
[31] H. Zhang,M. Tian,N. Oriuchi et al.,“11C-choline PET for the
detection of bone and soft tissue tumours in comparison with
FDG PET,” Nuclear Medicine Communications, vol. 24, no. 3,
pp. 273–279, 2003.
[32] A.C.Clavo,R.S.Brown,andR.L.Wahl,“Fluorodeoxyglucose
uptake in human cancer cell lines is increased by hypoxia,”
Journal of Nuclear Medicine, vol. 36, no. 9, pp. 1625–1632,
1995.
[33] R. Katz-Brull and H. Degani, “Kinetics of choline transport
and phosphorylation in human breast cancer cells; NMR
applicationofthezerotransmethod,”AnticancerResearch,v ol.
16, no. 3, pp. 1375–1380, 1996.